ReviewOncoimmunology2014
Trial Watch: DNA vaccines for cancer therapy.
Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 106 citations in OpenAlex.
- Smart Multifunctional Nanoparticles in Cancer Theranostics: Progress and Prospect.Pharmaceutical nanotechnology · 2025Review
- Review
- Anti-cancer activity of human gastrointestinal bacteria.Medical oncology (Northwood, London, England) · 2022Review
- Evasion before invasion: Pre-cancer immunosurveillance.Oncoimmunology · 2021Article
- Nanoparticle cancer vaccines: Design considerations and recent advances.Asian journal of pharmaceutical sciences · 2020Review
- Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy.Oncotarget · 2020Article
- Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.Frontiers in immunology · 2018Review
- Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.International journal of molecular sciences · 2017Review
- Bovine herpesviruses induce different cell death forms in neuronal and glial-derived tumor cell cultures.Journal of neurovirology · 2016Article
- Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology · 2016Review
- Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.Oncoimmunology · 2015Article
- Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Trial watch: Naked and vectored DNA-based anticancer vaccines.Oncoimmunology · 2015Article
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Cancer and the gut microbiota: an unexpected link.Science translational medicine · 2015Review
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma.Oncoimmunology · 2014Article
- Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology · 2014Review
- Trial Watch: Radioimmunotherapy for oncological indications.Oncoimmunology · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past 2 decades, the possibility that preparations capable of eliciting tumor-specific immune responses would mediate robust therapeutic effects in cancer patients has received renovated interest. In this context, several approaches to vaccinate cancer patients against their own malignancies have been conceived, including the administration of DNA constructs coding for one or more tumor-associated antigens (TAAs). Such DNA-based vaccines conceptually differ from other types of gene therapy in that they are not devised to directly kill cancer cells or sensitize them to the cytotoxic activity of a drug, but rather to elicit a tumor-specific immune response. In spite of an intense wave of preclinical development, the introduction of this immunotherapeutic paradigm into the clinical practice is facing difficulties. Indeed, while most DNA-based anticancer vaccines are well tolerated by cancer patients, they often fail to generate therapeutically relevant clinical responses. In this Trial Watch, we discuss the latest advances on the use of DNA-based vaccines in cancer therapy, discussing the literature that has been produced around this topic during the last 13 months as well as clinical studies that have been launched in the same time frame to assess the actual therapeutic potential of this intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.